Triangle firm agrees to manufacture European company's kidney drug

A Triangle contract, development and manufacturing organization has helped a pharmaceutical company from the Netherlands get its drug for acute kidney disease to Phase 3 clinical trials. Now it's preparing to help that company prepare the drug for a commercial launch. Durham-based KBI Biopharma announced Thursday that it had entered into a commercial manufacturing agreement with AM-Pharma for its recombinant human Alkaline Phosphatase (recAP) program intended to treat acute kidney injury associated…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news